National Alliance of State Prostate Cancer Coalitions Presents: "The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer"
NASPCC Webinar Series Presents:
“The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer”
With Dr. Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University.
The 1-hour Webinar will take place on Wednesday, November 4, 2020 at 7:00 pm – 8:00 pm Eastern and a replay will be available afterward.
To register for this event, please click here
Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 170 peer-reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.